Diabetes control with vildaGliptin and vildagliptin/mEtformin) study showed that vildagliptin is effective in patients with type 2 diabetes mellitus (T2DM) who have suboptimal glycemic control on metformin monotherapy in the real-world setting, confirming the results of previous randomized clinical trials (RCTs).
METHODS
• This study used the IMS Core Diabetes Model (CDM) 1, 2 , a validated 3 and established diabetes model, to evaluate the costs and outcomes of metformin + vildagliptin (M+V) compared to metformin + sulfonylurea (M+S), based on data derived from the EDGE study worldwide.
• EDGE was a prospective, 1-year, worldwide, 'real-life' observational, non-interventional study, which compared the effectiveness and safety of treatment intensification with vildagliptin vs other oral anti-diabetics, as per clinical judgment, in patients with T2DM inadequately controlled with monotherapy, across five world regions (East Asia, Europe, India, Latin America and the Middle East) 4 .
• M+V was associated with HbA1c and BMI changes of -1.19% and 0.199kg/m 2 , respectively. Corresponding data for M+S were -0.99% and 0.707kg/m 2 , respectively.
• Published network meta-analysis data were used to populate the CDM with hypoglycemia rates and effectiveness data for basal insulin (BI) rescue therapy (applied to both arms at HbA1c threshold levels of 7.5%), and was associated with HbA1c and BMI changes of -0.82% and 0.545kg/m 2 , respectively 5 .
• Annual rates of hypoglycemia were estimated from odds ratios obtained from the same systematic review 5 ; 8.22, 1.05 and 5.2 for M+S, M+V and BI add-on therapy to metformin vs. metformin monotherapy, respectively.
• The background risk of hypoglycemia with metformin monotherapy was sourced from the UKPDS 73 6 ; 1.7 and 0.3 events per 100 patient-years for symptomatic and severe episodes, respectively.
• Annual treatment costs were expected to be $67.6, $2,520.0 and $1,869.7 for M+S, M+V and BI, respectively, based on wholesale acquisition costs (WAC) obtained from standard US list prices (2012). Table 1 and Table 2 summarize the key demographics and effectiveness data modelled.
• The model was run over a lifetime using standard CORE model costs ($ US) and health utilities, with costs and benefits discounted at 3.0%. 
RESULTS
• Predicted quality-adjusted life expectancy (QALE) was 11.14 and 11.07 years in patients treated with M+V and M+S, respectively ( Table 3 ).
• Total direct costs were estimated at $90,788 and $85,692 for patients treated with M+V and M+S, respectively ( Table 3 ).
• Incremental differences between M+V and M+S were 0.07 for QALE and $5,096 for total costs, yielding an incremental cost-effectiveness ratio (ICER) of $72,800 ( Table 4 ).
• Differences in total costs were predominantly therapy-related (Figure 1) . 
DISCUSSION
• The economic analysis of real-life observational studies provides useful data to quantify the extent to which new interventions provide value for money in clinical practice.
• Furthermore, the analysis of patient-level data from studies like EDGE would further enhance this output by providing clinicians and payers with data on both patient and geographic characteristics associated with maximum treatment-related health economic value.
CONCLUSIONS
• In the real-world setting, compared to sulfonylureas, vildagliptin was estimated to be cost effective using US ICER thresholds.
• These data further highlight the potential role of real-world data in assessing health economic value.
